3.86 Lenvatinib plus Pembrolizumab or Everolimus for Advanced RCC with Dr. Karine Tawagi - podcast episode cover

3.86 Lenvatinib plus Pembrolizumab or Everolimus for Advanced RCC with Dr. Karine Tawagi

Plenary Session - inactive due to federal service
May 28, 2021•35 min
--:--
--:--
Listen in podcast apps:
Metacast
Spotify
Youtube
RSS

Episode description

Today we bring back our popular Journal Club with a Fellow segment. We're joined by Dr. Karine Tawagi of the Oschner Clinic in Louisiana to discuss the CLEAR trial: "Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma" as published in the New England Journal of Medicine. CLEAR: doi.org/10.1056/NEJMoa2035716 Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew
For the best experience, listen in Metacast app for iOS or Android
Open in Metacast
3.86 Lenvatinib plus Pembrolizumab or Everolimus for Advanced RCC with Dr. Karine Tawagi | Plenary Session - inactive due to federal service podcast - Listen or read transcript on Metacast